Best of ASCO Features Three Studies Led by US Oncology Affiliated Physicians
More than 50 physicians and oncology experts affiliated with US Oncology presented orals, posters and poster discussions at the 46th ASCO Annual Meeting
THE WOODLANDS, Texas, June 10 /PRNewswire/ -- Three clinical
trials studies with prominent authorship by physicians affiliated
with the United Network of US Oncology have been selected to be
featured in the Best of ASCO to be held July 16 - 17 in San
Francisco and July 23 -24 in Boston.
(Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO)
The American Society of Clinical Oncology (ASCO) hosts its 46th
Annual Meeting June 4-8 at McCormick Place in Chicago. The ASCO
Annual Meeting is the premier educational and scientific event in
the oncology community. It highlights the most advanced treatments
in cancer care and attracts more than 23,000 cancer specialists
from around the world. This year's annual meeting will feature
clinical trials studies that include contributions from more than
50 clinical investigators affiliated with US Oncology, Inc., the
leading integrated oncology company uniting the largest network of
oncologists in the United States to improve the quality of patient
care and advance the science of cancer care.
Physicians affiliated with US Oncology contributed to more than
four dozen studies that will be presented at the ASCO annual
meeting, including the three listed below which have been chosen to
be featured in the Best of ASCO:
-- Abstract #CRA1004^: A phase III study (EMBRACE) of eribulin mesylate
versus treatment of physician's choice in patients with locally
recurrent or metastatic breast cancer previously treated with an
anthracycline and a taxane. (C. Twelves et al)
-- Abstract #1005: A meta-analysis of overall survival data from three
randomized trials of bevacizumab (BV) and first-line chemotherapy as
treatment for patients with metastatic breast cancer (MBC). (J.
O'Shaughnessy et al)
-- Abstract #LBA5008: Phase III trial of induction gemcitabine or
paclitaxel plus carboplatin followed by elective paclitaxel
consolidation in advanced ovarian cancer: Final safety and efficacy
report. (M. Teneriello et al)
At the ASCO 46th Annual Meeting, US Oncology affiliated
physicians have contributed to seven studies that will were
presented orally - four oral abstracts, two clinical science
symposiums and one late breaking; seven poster discussions; 25
general poster discussions; four trials in progress; and two
published studies. For a full list of US Oncology affiliated
presentations, see the ASCO press release in the newsroom at
www.usoncology.com.
In addition, Daniel D. Von Hoff, MD, FACP, received the 2010
David A. Karnofsky Memorial Award and Lecture for his outstanding
achievements in cancer research and for his impact on the treatment
of patients with cancer. Dr. Von Hoff is an internationally
recognized physician-scientist who has contributed to the
development of numerous anticancer agents, including paclitaxel,
docetaxel, irinotecan and gemcitabine. He currently serves as
physician-in-chief for the Translational Genomics Institute in
Phoenix, Arizona, chief scientific officer at US Oncology and
Scottsdale Healthcare, and clinical professor of medicine at The
University of Arizona College of Medicine. Dr. Von Hoff also serves
as lead physician of the Translational Oncology Program (TOP) for
US Oncology. The TOP program offers Phase I clinical trial studies,
which often offer first-in-human agents. He is also responsible for
bringing many new compounds to US Oncology Research for
studies.
John V. Cox, DO, FACP, Texas Oncology is a recipient of the ASCO
Statesman Award. This award recognizes ASCO members for their
extraordinary volunteer service, dedication, and commitment to
ASCO. Recipients of the 2010 Statesman Award have given 20 years of
volunteer service.
"We are honored that ASCO continues to recognize the great work
of the investigators in the United Network of US Oncology," says
Roy Beveridge, MD, medical director for US Oncology. "Each year,
dozens of community-based physicians in our affiliated network
present their study findings at this prestigious annual meeting.
Within every study lies the opportunity for improved care for
cancer patients. At US Oncology, we are proud to be working in
association with ASCO in the forefront of improved cancer
care."
About US Oncology
US Oncology, Inc. is the nation's leading integrated oncology
company. By uniting the largest community-based cancer treatment
and research network in America, US Oncology expands patient access
to high-quality care and advances the science of cancer care.
Headquartered in The Woodlands, Texas, US Oncology is affiliated
with more than 1,300 community-based oncologists, and works with
patients, hospitals, payers, and the medical industry across all
phases of the cancer research and delivery system. By promoting the
use of innovative technology, clinical research, evidence-based
medicine and shared best practices, US Oncology improves patient
outcomes and offers a better patient experience. For more
information, visit www.usoncology.com.
About US Oncology Research
US Oncology conducts clinical research through US Oncology
Research, its wholly-owned subsidiary and the nation's largest
community-based cancer research network. US Oncology Research has
experienced investigators and dedicated research nurses who
specialize in Phase I through Phase IV oncology clinical trials. US
Oncology Research serves more than 80 sites in 200 locations
managing more than 200 active trials at any given time. The
research network has enrolled more than 42,900 patients in more
than 700 trials since its inception and has contributed to the
development of 40 cancer therapies approved by the FDA. For more
information call (866) 216-5053 or visit
www.usoncology.com/oncologists.
Photo: AP Archive: http://photoarchive.ap.org/
http://photos.prnewswire.com/prnh/20100517/DA06089LOGO
PRN Photo Desk, photodesk@prnewswire.com/
Source: US Oncology, Inc.
CONTACT: Jennifer Horspool, +1-281-863-6739,
Jennifer.Horspool@usoncology.com,
or Claire Crye, +1-281-863-6783,
Claire.Crye@usoncology.com,
both of US Oncology, Inc.
Web Site: http://www.usoncology.com/
Posted: June 2010
